Hakan Bozcuk
Overview
Explore the profile of Hakan Bozcuk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis
Mutlu H, Bozcuk H
J Cancer Res Ther
. 2023 Jun;
19(2):394-402.
PMID: 37313915
Background: Prostate cancer (PC) is one of the most common cancer types in men. In addition to androgen-deprivation therapy (ADT), new generation agents have provided survival advantages to patients with...
2.
Mutlu H, Bozcuk H, Artac M, Eser I
J Cancer Res Ther
. 2023 May;
19(Supplement):S6-S11.
PMID: 37147977
Background: Small-cell lung cancer (SCLC) has a poor prognosis. For the last 30 years, first-line systemic treatment has remained unaltered. After the integration of ımmunotherapy, a new first-line gold standard,...
3.
Bozcuk H, Coskun H, Ilhan Y, Sezgin Goksu S, Yildiz M, Bayram S, et al.
Support Care Cancer
. 2021 Nov;
30(3):2621-2629.
PMID: 34816328
Purpose: Febrile neutropenia resulting from chemotherapy is a significant cause of morbidity and mortality in cancer patients. We had previously published the associates of the risk of febrile neutropenia, and...
4.
Sarier M, Usta S, Turgut H, Ozturk S, Soylu A, Emek M, et al.
Urol J
. 2021 May;
19(1):45-49.
PMID: 33931844
Purpose: The association between the human papillomavirus (HPV) and anogenital carcinomas is well established. However, despite its anatomic adjacency, the relationship between HPV and urothelial carcinoma of the bladder (UCB)...
5.
Bozcuk H, Artac M, Mutlu H, Sever O, Yildirim M
J Oncol Pharm Pract
. 2020 Oct;
27(2):405-413.
PMID: 33040676
Background: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PDL-1) inhibitors have improved survival over chemotherapy in advanced Non- Small Cell Lung Cancer (NSCLC). However, it is unclear if there are...
6.
Bozcuk H, Yildirim M, Sever O, Mutlu H, Artac M
J Cancer Res Ther
. 2020 Sep;
16(4):828-837.
PMID: 32930126
Background: Checkpoint inhibitors (CPIs) have improved survival compared to chemotherapy alone in advanced nonsmall-cell lung cancer (NSCLC). This article aims to compare indirect evidence and rank the effect of different...
7.
Ergen S, Dincbas F, Yucel B, Altinok P, Akyurek S, Kirakli E, et al.
Clin Respir J
. 2020 May;
14(9):871-879.
PMID: 32470205
Introduction: To evaluate the clinical and dosimetric parameters that increase the risk of radiation pneumonitis (RP) in locally advanced non-small cell lung cancer (NSCLC) patients treated with concomitant chemoradiotherapy of...
8.
Kaya V, Yildirim M, Yazici G, Gunduz S, Bozcuk H, Paydas S
Asian Pac J Cancer Prev
. 2018 May;
19(5):1169-1173.
PMID: 29801396
Background: Triple-negative breast cancer (TNBC) is a sub-group of breast cancers with a particularly poor
prognosis. The results of studies investigating the role of platinum-based chemotherapy (PBC) in metastatic TNBC...
9.
Artac M, Uysal M, Karaagac M, Korkmaz L, Er Z, Guler T, et al.
J Gastrointest Cancer
. 2016 Oct;
48(2):176-180.
PMID: 27714653
Purpose: Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors...
10.
Coskun H, Kargi A, Ozdogan M, Bozcuk H, Savas B
Turk J Haematol
. 2016 Jun;
27(1):51-2.
PMID: 27265802
No abstract available.